MaxCyte reported second quarter 2026 financial results with total revenue of $7.3 million, a 15% decrease from the prior year period. Core business revenue was $6.5 million, down 21%, while Strategic Platform License (SPL) Program-related revenue rose to $0.8 million from $0.3 million. The company posted a net loss of $8.9 million compared to $12.4 million in the same period last year, with operating expenses reduced to $15.8 million from $21.2 million. Gross profit was $5.6 million with a 77% gross margin. Management reiterated full-year 2026 revenue guidance of $30 million to $32 million and expects to end the year with at least $130.5 million in cash, excluding further share repurchases. The company has repurchased approximately $5.5 million of common stock under its authorized program and announced a strategic multi-platform technology license partnership with Genentech following the quarter-end.

MaxCyte, Inc. has regained compliance with Nasdaq Listing Rule 5450(a)(1) after its common stock closing bid price was above $1.00 for 10 consecutive business days between May 25, 2026 and June 9, 2026. MaxCyte, Inc. operates in the life sciences industry and provides cell and gene therapy development tools.